🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy

RecruitingNAAges 18 Years - anyAllFondazione IRCCS Ca' Granda, Ospedale Maggiore Po…
NCT07558447 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn whether extracellular vesicles (EVs) in the blood can be used as biomarkers to predict chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients receiving chemotherapy with taxanes, platinum compounds, or antimitotic drugs. The main questions the study aims to answer are whether blood levels of EVs change in patients who develop CIPN during and after chemotherapy and whether specific features of EVs, including lipids and microRNAs, are associated with the development and severity of CIPN. Participants will be followed from before the start of chemotherapy until six months after treatment ends to evaluate how changes in EVs relate to nerve damage caused by chemotherapy. During the study, participants will provide blood samples before chemotherapy, at the end of treatment, and six months later for measurement and molecular analys

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Has signed the informed consent form * Is 18 years of age or older * Is male or female * Has breast cancer and is scheduled to receive paclitaxel, docetaxel, eribulin, capecitabine, or carboplatin as part of standard care * Has gastrointestinal cancer and is scheduled to receive oxaliplatin or capecitabine as part of standard care * Has lung cancer and is scheduled to receive cisplatin, carboplatin, or docetaxel as part of standard care * Has urologic cancer and is scheduled to receive carboplatin, cisplatin, paclitaxel, docetaxel, or enfortumab vedotin as part of standard care * Has head and neck cancer and is scheduled to receive carboplatin, paclitaxel, or cisplatin as part of standard care Exclusion Criteria: * Has already been diagnosed with CIPN * Has a neurodegenerative disease
💊

What it tests

  • CIPN assessment
  • EV blood analysis
📍

Where

1 site
SC Oncologia Medica Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy